Taweesak Wannachalee1,2, Adina F Turcu1, Irina Bancos3, Mouhammed Amir Habra4, Anca M Avram5, Hubert H Chuang6, Steven G Waguespack4, Richard J Auchus1,7. 1. Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan. 2. Faculty of Medicine Siriraj Hospital, Division of Endocrinology and Metabolism, Mahidol University, Bangkok, Thailand. 3. Division of Endocrinology, Diabetes, Metabolism & Nutrition, Mayo Clinic, Rochester, Michigan. 4. Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, Michigan. 6. Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Department of Pharmacology, University of Michigan, Ann Arbor, Michigan.
Abstract
OBJECTIVES: Localization of ectopic ACTH-secreting tumours causing Cushing syndrome (ECS) is essential for clinical management, yet often difficult. [68 Ga]-DOTATATE PET/CT ([68 Ga]-DOTA-(Tyr3 )-octreotate)] is an FDA-approved high-resolution diagnostic tool for imaging neuroendocrine tumours. Data on the clinical utility of [68 Ga]-DOTATATE in patients with ECS, however, are scarce. The objectives of this study were to determine the efficacy for ECS localization and the clinical benefit of [68 Ga]-DOTATATE imaging. METHOD: We conducted a retrospective review of all cases with ECS evaluated with [68 Ga]-DOTATATE from November 2016 through October 2018 at three referral centres. The clinical benefit of [68 Ga]-DOTATATE was based on detection of new tumours and resultant changes in management. RESULTS: Over the study period, 28 patients with ECS underwent [68 Ga]-DOTATATE: 17 for identification of the primary tumour and 11 during follow-up. [68 Ga]-DOTATATE identified the suspected primary ECS in 11/17 patients (65%). Of these, nine patients underwent surgery: eight with confirmed ECS (5 bronchial, 1 thymic, 1 pancreatic and 1 metastatic neuroendocrine tumour of unknown primary origin) and one patient with a false-positive scan (adrenal gland). Of the 11 patients with ECS who underwent [68 Ga]-DOTATATE evaluation during follow-up, the study led to changes in clinical management in 7/11 (64%) patients. CONCLUSIONS: [68 Ga]-DOTATATE is sensitive in detecting primary and metastatic ECS, often identifies occult tumours after conventional imaging, and impacts clinical care in the majority of patients.
OBJECTIVES: Localization of ectopic ACTH-secreting tumours causing Cushing syndrome (ECS) is essential for clinical management, yet often difficult. [68 Ga]-DOTATATE PET/CT ([68 Ga]-DOTA-(Tyr3 )-octreotate)] is an FDA-approved high-resolution diagnostic tool for imaging neuroendocrine tumours. Data on the clinical utility of [68 Ga]-DOTATATE in patients with ECS, however, are scarce. The objectives of this study were to determine the efficacy for ECS localization and the clinical benefit of [68 Ga]-DOTATATE imaging. METHOD: We conducted a retrospective review of all cases with ECS evaluated with [68 Ga]-DOTATATE from November 2016 through October 2018 at three referral centres. The clinical benefit of [68 Ga]-DOTATATE was based on detection of new tumours and resultant changes in management. RESULTS: Over the study period, 28 patients with ECS underwent [68 Ga]-DOTATATE: 17 for identification of the primary tumour and 11 during follow-up. [68 Ga]-DOTATATE identified the suspected primary ECS in 11/17 patients (65%). Of these, nine patients underwent surgery: eight with confirmed ECS (5 bronchial, 1 thymic, 1 pancreaticand 1 metastatic neuroendocrine tumour of unknown primary origin) and one patient with a false-positive scan (adrenal gland). Of the 11 patients with ECS who underwent [68 Ga]-DOTATATE evaluation during follow-up, the study led to changes in clinical management in 7/11 (64%) patients. CONCLUSIONS: [68 Ga]-DOTATATE is sensitive in detecting primary and metastatic ECS, often identifies occult tumours after conventional imaging, and impacts clinical care in the majority of patients.
Authors: Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2008-03-11 Impact factor: 5.958
Authors: Andrea M Isidori; Gregory A Kaltsas; Carlotta Pozza; Vanni Frajese; John Newell-Price; Rodney H Reznek; Paul J Jenkins; John P Monson; Ashley B Grossman; G Michael Besser Journal: J Clin Endocrinol Metab Date: 2005-11-22 Impact factor: 5.958
Authors: Shamim Ejaz; Rena Vassilopoulou-Sellin; Naifa L Busaidy; Mimi I Hu; Steven G Waguespack; Camilo Jimenez; Anita K Ying; Maria Cabanillas; Maher Abbara; Mouhammed Amir Habra Journal: Cancer Date: 2011-03-15 Impact factor: 6.860
Authors: Ioannis Ilias; David J Torpy; Karel Pacak; Nancy Mullen; Robert A Wesley; Lynnette K Nieman Journal: J Clin Endocrinol Metab Date: 2005-05-24 Impact factor: 5.958
Authors: C de Bruin; L J Hofland; L K Nieman; P M van Koetsveld; A M Waaijers; D M Sprij-Mooij; M van Essen; S W J Lamberts; W W de Herder; R A Feelders Journal: J Clin Endocrinol Metab Date: 2011-11-16 Impact factor: 5.958
Authors: Marina S Zemskova; Bhaskar Gundabolu; Ninet Sinaii; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Iffat Chowdhury; Ahmed M Gharib; Lynnette K Nieman Journal: J Clin Endocrinol Metab Date: 2010-01-20 Impact factor: 5.958
Authors: C de Bruin; R A Feelders; A M Waaijers; P M van Koetsveld; D M Sprij-Mooij; S W J Lamberts; L J Hofland Journal: J Mol Endocrinol Date: 2008-10-13 Impact factor: 5.098
Authors: Maria Fleseriu; Richard Auchus; Irina Bancos; Anat Ben-Shlomo; Jerome Bertherat; Nienke R Biermasz; Cesar L Boguszewski; Marcello D Bronstein; Michael Buchfelder; John D Carmichael; Felipe F Casanueva; Frederic Castinetti; Philippe Chanson; James Findling; Mônica Gadelha; Eliza B Geer; Andrea Giustina; Ashley Grossman; Mark Gurnell; Ken Ho; Adriana G Ioachimescu; Ursula B Kaiser; Niki Karavitaki; Laurence Katznelson; Daniel F Kelly; André Lacroix; Ann McCormack; Shlomo Melmed; Mark Molitch; Pietro Mortini; John Newell-Price; Lynnette Nieman; Alberto M Pereira; Stephan Petersenn; Rosario Pivonello; Hershel Raff; Martin Reincke; Roberto Salvatori; Carla Scaroni; Ilan Shimon; Constantine A Stratakis; Brooke Swearingen; Antoine Tabarin; Yutaka Takahashi; Marily Theodoropoulou; Stylianos Tsagarakis; Elena Valassi; Elena V Varlamov; Greisa Vila; John Wass; Susan M Webb; Maria C Zatelli; Beverly M K Biller Journal: Lancet Diabetes Endocrinol Date: 2021-10-20 Impact factor: 32.069
Authors: Siyuan Yu; Michael Karsy; Jeffrey Miller; Stephanie R Beldick; Mark T Curtis; Marc Rosen; James J Evans Journal: J Neurosurg Case Lessons Date: 2021-07-05
Authors: Yu Xing Zhao; Wan Lu Ma; Yan Jiang; Guan Nan Zhang; Lin Jie Wang; Feng Ying Gong; Hui Juan Zhu; Lin Lu Journal: Front Endocrinol (Lausanne) Date: 2022-02-18 Impact factor: 5.555
Authors: David Kishlyansky; Gregory Kline; Amita Mahajan; Konstantin Koro; Janice L Pasieka; Patrick Champagne Journal: Endocrinol Diabetes Metab Case Rep Date: 2022-03-01